Navigation Links
Frost & Sullivan Predicts Growth for the European Vaccines Market
Date:9/11/2012

LONDON, Sept. 11, 2012 /PRNewswire/ -- As vaccine manufacturers increasingly tend to leverage on novel technologies, and potential late-stage vaccine candidates progress the pipeline and reach the commercialization stage, the European vaccines market is expected to witness significant growth rates. Next generation vaccines such as edible plant-based vaccines could also have a significant impact on vaccines development.

New analysis from Frost & Sullivan, Analysis of the European Vaccines Market, (www.pharma.frost.com), finds that the European vaccines market earned revenues of $6.36 billion in 2011 and estimates this to reach $12.05 billion in 2018 at a compound annual growth rate (CAGR) of 9.6% from 2011-2018.

The high levels of unmet medical needs for diseases such as AIDS, malaria and tuberculosis - which affect millions of people every year and contribute to increasing healthcare expenditure - present huge growth potential and untapped market opportunities, thereby fuelling increased R&D investments and government support for vaccine development.

"The future growth of the vaccine industry is likely to be propelled by the adult vaccines segment," notes Frost & Sullivan Senior Research Analyst Aiswariya Chidambaram. "The tremendous success rates of the recently launched influenza and HPV vaccines have attracted the attention of market participants towards the adult vaccines. The vast majority of the vaccines in pipeline are novel, innovative vaccines based on new antigens, targeting malaria, tuberculosis, dengue fever, allergies and herpes."

Anticipation of capacity demand remains a key challenge for vaccine manufacturers, particularly during pandemic outbreak of diseases.

"Speculation of vaccine production capacity considering unanticipated needs such as pandemic outbreaks, epidemics and bioterrorism is likely to have a huge impact on the growth and sustenance of vaccine manufacturers in Europe," adds Chidambaram. "Vaccine manufacturers are under the compulsion to maintain excess reserve supply owing to the tender-based vaccine procurement, lest they miss out on huge business opportunities."

Accurate estimation of capacity demand and product differentiation will therefore be critical for market participants to garner a substantial share of the market.

"The highly fragmented nature of the European market will require market participants to accurately predict manufacturing capacity and fulfil global requirements during emergency situations, thereby enabling them to stay ahead of competition and prevent being hit by excess or inadequate capacity," concludes Chidambaram.

If you are interested in more information on this study, please send an email with your contact details to Anna Zanchi, Corporate Communications, at anna.zanchi@frost.com.

Analysis of the European Vaccines Market is part of the Pharmaceutical and Biotechnology Growth Partnership Service programme, which also includes research in the following markets: European Biosimilars Market and European Pharmaceutical and Biotech Contract Manufacturing Markets. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.

About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us:     Start the discussion
Join Us:           Join our community
Subscribe:       Newsletter on "the next big thing"
Register:         Gain access to visionary innovation

Contact:
Anna Zanchi
Corporate Communications – Europe
P: 0039 02 46514819
E: anna.zanchi@frost.com
http://www.frost.com


'/>"/>
SOURCE Frost & Sullivan
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
2. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
3. European Thrombosis Therapeutics Market is Experiencing an Urgent Need for Enhanced Products, Says Frost & Sullivan
4. Frost & Sullivan Research Preview: Top 20 Telehealth Markets
5. Heightened Awareness, Coupled with Expanding Patient Pool, Stimulates Sleep Apnea Diagnostics and Sleep Services Market, Says Frost & Sullivan
6. Frost & Sullivan Recognizes Labcyte for its Commitment to Innovation and Addressing Unmet Needs in the Liquid Handling Market
7. MicroRNA Research to Trigger Tremendous Growth in Related Tools Market, Says Frost & Sullivan
8. Frost & Sullivan: Developing Integration Capabilities Presents a Real Opportunity for Vendors in the European CIS Market
9. Frost & Sullivan: Expanding Sample Prep Market Supports Growth Trends in Molecular Diagnostics Markets
10. Electronic Medical Records Progress from an Enterprise-Centric Solution to a Customer-Specific Application, Finds Frost & Sullivan
11. Frost & Sullivan to Host Complimentary Web Conference: Concerns and Solutions for the Anaesthesia Equipment and Associated Peripherals Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... 2016 194 Mitgliedsstaaten ... Eliminierung von viraler Hepatitis    Am ... eingegangen, virale Hepatitis bis 2030 zu eliminieren. ... Assembly haben sich die Staaten einstimmig dafür entschieden, ... Viral Hepatitis Strategy) zu verabschieden, was das bisher ...
(Date:5/30/2016)... , May 30, 2016 ... "Healthcare Analytical Testing Services Market by Type (Stability, ... Services), by End User (Pharmaceutical Companies, Medical Device ... MarketsandMarkets, The market witnessed healthy growth during the ... a CAGR of 11.3% between 2016 and 2021 ...
(Date:5/30/2016)... , May 30, 2016 ... 2016" market research report with comprehensive information on ... comparative analysis at various stages, therapeutics assessment by ... administration (RoA) and molecule type, along with latest ... also reviews key players involved in the therapeutic ...
Breaking Medicine Technology:
(Date:5/31/2016)... ... 31, 2016 , ... Spartan Bioscience today introduced the Spartan ... convenience. , The Cube is exceptionally small—it takes up the space of a ... into any space, whether in a hospital, doctor’s office, or pharmacy. , The ...
(Date:5/31/2016)... ... May 31, 2016 , ... Like jewels in a crown, ... know – London is home to Ontario’s leading day spa and one of Canada’s ... Tamba began with a unique concept to combine spa services with hair and ...
(Date:5/31/2016)... ... ... In his latest video, renowned AstroNumerologist Jesse Kalsi reveals ... candidate Donald Trump as an example, Kalsi describes the way AstroNumerology conveys the ... numbers up,” says Kalsi. “It is about looking at each individual number, since ...
(Date:5/31/2016)... ... 31, 2016 , ... Interest is on the rise for using the CRISPR-Cas9 ... tool for RNAi hit validation. A key reason may be that high-throughput synthesis—combined with ... CRISPR RNA (crRNA) collections in arrayed formats. , Arrayed crRNA screens ...
(Date:5/31/2016)... ... , ... In a recent interview on The Greenburgh Report radio show hosted ... WVOX (1460 AM), leading medical insurance advocate Adria Goldman Gross discussed several eye-opening ... maelstrom.” , During the interview with Mr. Feiner that aired on May 7, ...
Breaking Medicine News(10 mins):